Eli Lilly shepherds its $1.1B contender through another PhIII challenge on the way to the FDA
Just 6 days after Eli Lilly execs ID’d its $1.1 billion atopic dermatitis drug lebrikizumab as one of its top late-stage drug candidates, the pharma giant has followed up with another round of positive late-stage data as it paves the way to planned regulatory filings in 2022.
The Christmas week statement from Lilly included little by way of hard data — the big outfit typically reserves that for its science conferences — but researchers touted a clean sweep of the primary and all secondaries in its 3rd round of late-stage results.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.